-- Scott Roberts
MONDAY, Nov. 5 (HealthDay News) -- Approval of the anti-clotting
drug Xarelto (rivaroxaban) has been expanded by the U.S. Food and
Drug Administration to include treating deep vein thrombosis (DVT)
or pulmonary embolism.
DVT occurs when a blood clot forms in a vein deep in the body.
If a clot breaks away and travels to an artery in the lungs, it
becomes a potentially deadly condition called a pulmonary
Xarelto was approved last year to treat clots stemming from knee
or hip replacement and to lessen the risk of stroke in people with
a form of abnormal heart rhythm called non-valvular atrial
The drug's newest approvals were given based on clinical studies
involving 9,478 people, the FDA said in a news release. As with
other anti-clotting drugs, bleeding is the most common side
Xarelto is produced by Janssen Pharmaceuticals, based in
The FDA has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.